Endocrine response: Is CGAthe key?
- Valerie Speirs1
© Biomed Central Ltd 2001
Received: 30 April 2001
Accepted: 20 August 2001
Published: 1 December 2001
Oestrogen receptor (ER) is an established prognostic marker in breast cancer and expressed in about two thirds of all patients. The presence of ER is used routinely to predict response to adjuvant endocrine therapy. However, not all patients with ER-positive tumours respond, so there is a need to identify alternative markers of endocrine responsiveness. In this study, the authors evaluated the role of the CGA gene (coding for the a subunit of glycoprotein) as a novel ER-responsive gene in a cohort of human breast tumours.
Overexpression of CGA was observed in 44 of the 131 breast tumours tested. Significant associations were noted between CGA overexpression and features indicating a low level of biological aggressiveness, including histological grades I and II, ER a and progesterone receptor. Overexpression of CGA was not observed in ER-negative tumours, indicating its association with ER responsiveness, and immunohistochemical analysis showed CGA was expressed exclusively in ER-positive tumour cells.
The CGA gene has the potential to offer a more refined approach for the selection of patients for endocrine therapy. Future studies should focus on the expression of CGA in in tumours sensitive or resistant to tamoxifen to determine if it is associated with survival advantage. On a technical note, high throughput screening of CGA in a clinical setting would require further validation of the immunohistochemical technique, as TaqManR real-time PCR requires specialised and expensive equipment which may not be available to many pathology labs. Together with established markers of endocrine response, CGAis an attractive new candidate which could help decide which patients might benefit from adjuvant endocrine therapy.
TaqManR real-time PCR, immunohistochemistry